

**MACH7 COMPLETES CAPITAL RAISE**

- **Mach7 successfully completes \$2.5 million capital raising via institutional placement**
- **Placement well supported by leading Australian institutions**
- **Proceeds will be used to accelerate product and business development**
- **Funding will assist in transitioning the company towards profitability**

**Melbourne, Australia; 2 May 2016:** Mach7 Technologies Limited (**Mach7**) (ASX:**M7T**) today announced that it has successfully raised its funding target of \$2.5m. Petra Capital acted as lead manager for the Placement.

Mach7 has raised a total of \$2.52m (before costs) at an issue price of 6 cents per share. This represents a discount of 9% to the closing share price of 6.6 cents on 27 April 2016. As a result of the placement, the company will issue a total of 42 million new ordinary shares, which are expected to be allotted on or before 5 May 2016. This placement was approved by shareholders at the Company's general meeting held 31 March 2016.

The placement was well supported by new and existing institutional and sophisticated investors.

The proceeds from the capital raise will be applied to new product development, core platform technology enhancements and increased sales and marketing capabilities.

Mach7 CEO, Albert Liong, commented: "The placement proceeds will provide Mach7 with additional funding as we undertake the important transition from being a development company to a company that can deliver profitability. We welcome our new institutional shareholders and thank all shareholders for their ongoing support."

**About Mach7 Technologies:**

Mach7 Technologies is a global provider of enterprise image management systems that allow healthcare enterprises to easily identify, connect, and share diagnostic image and patient care intelligence where and when needed. Mach7's award-winning platform delivers image management including rapid record identification, integration, synchronisation and routing, advanced clinical viewing, and optimized vendor neutral archiving. Mach7 has locations in the U.S., Asia, Australia, Africa and the Middle East. For more information, visit [www.mach7t.com](http://www.mach7t.com)

Mach7's wholly-owned subsidiary, 3D Medical Limited, provides medical specific 3D printing is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. For more information, visit [www.3dmedical.com.au](http://www.3dmedical.com.au)

**For more information, contact:**

Albert Liong  
CEO  
+1 650 743 0167  
[albert.liong@mach7t.com](mailto:albert.liong@mach7t.com)

Jenni Pilcher  
CEO Australia, CFO  
+61 3 9464 2222  
[jenni.pilcher@mach7t.com](mailto:jenni.pilcher@mach7t.com)